Clinical Trials Browser

OTHER × Mastocytosis, Systemic × 1 year × Clear all

Osteoporosis, Mastocytosis, Systemic

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00769587 2025-09-22

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

Completed

MyeloidOther neoplasm

Precancerous Conditions, Mastocytosis, Systemic

NCT07142473 2025-08-26

MaRe

Recruiting

600 enrolled

DermatologicMyeloid

Mastocytosis, Cutaneous, Mastocytosis, Systemic

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed

10 enrolled 4 charts

Myeloid

Mastocytosis, Systemic

Clinical Trials

DenosuMast

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

MaRe

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis